Celcuity Inc. (CELC)

15.22 -0.55 (-3.49%) As of 01:02PM EDT. Market open.

Celcuity Inc.

16305–36th Avenue North
Suite 100
Minneapolis, MN 55446
United States
763 392 0767
https://www.celcuity.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 55

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Brian F. Sullivan	Co-Founder, Chairman & CEO	478.12k	N/A	1962
Dr. Lance G. Laing Ph.D.	Co-Founder, Chief Science Officer, VP, Secretary & Director	389.55k	N/A	1962
Ms. Vicky Hahne	Chief Financial Officer	281.59k	N/A	1966
Dr. John R. MacDonald Dabt, Ph., Ph.D.	Senior Vice President of R&D	N/A	N/A	1955
Ms. Sheri Smith	Acting Head of Clinical Operations	N/A	N/A	N/A
Mr. Igor Gorbatchevsky M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Eldon C. Mayer III, M.B.A.	Chief Commercial Officer	N/A	N/A	1961

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Corporate governance

Celcuity Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.